{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:33:42Z","timestamp":1778542422803,"version":"3.51.4"},"reference-count":30,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  In recent years the management of hepatitis C virus infection and the possibility of its eradication have been researched due to the importance that they represent in the health of the world population. Obtaining data that help to cope with this pathology improves the quality of life of those affected by it. The present study evaluated the effectiveness of direct-acting antiviral therapies provided by the Brazilian Ministry of Health in accordance to the Clinical Protocol and Therapeutic Guidelines of 2015.  OBJECTIVE:  To evaluate the epidemiological profile of patients with chronic hepatitis C and the rate of sustained virologic response using direct-acting antivirals of all individuals that attended the referral service for the treatment of chronic hepatitis C at the Hospital of the Federal University of Rio Grande.  METHODS:  This was an observational, retrospective\/prospective study with all patients with chronic hepatitis C who had their treatments available from December 2015 to August 2017 according to the criteria of the Clinical Protocol and Therapeutic Guidelines of 2015. In the first phase, the clinical and demographic variables of all individuals enrolled in a treatment for hepatitis C were selected and collected from the Reference Service database. In the second phase, treatment data were collected. The outcome variable, sustained virologic response, was defined as an undetectable viral load on the blood test three months after the end of treatment. The descriptive and bivariate analyzes were performed with Pearson\u2019s chi-square and Fisher\u2019s Exact test, adopting a P value \u22640.05 in the SPSS 20 software.  RESULTS:  Of the 252 participants in the study, 228 (90.5%) had a sustained virologic response, 55.2% were male with an average age of 58.6 years (SD\u00b19.1). Genotype 1 was the most prevalent, observed in 54.4% of the participants, and 87.4% of the patients had moderate\/advanced hepatic fibrosis. After the statistical analysis, it was observed that the individuals with genotype 3 and moderate\/advanced hepatic fibrosis had lower sustained virologic response rate (P=0.05 and P=0.04, respectively).  CONCLUSION:  It was observed that the use of direct-acting antivirals, in comparison to previous therapeutic regimens, increases the sustained virologic response, reaching all patients with mild fibrosis. This study provides information that helps in the hepatitis C treatment by showing that prescribing early treatment for patients without hepatic fibrosis and\/or genotype 3 virus could increase therapeutic effectiveness.<\/jats:p>","DOI":"10.1590\/s0004-2803.201900000-79","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T19:35:58Z","timestamp":1574883358000},"page":"394-398","source":"Crossref","is-referenced-by-count":3,"title":["SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY"],"prefix":"10.1590","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-5715","authenticated-orcid":false,"given":"Andr\u00e9a Delfino","family":"TORRES","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-2957","authenticated-orcid":false,"given":"Juc\u00e9li Maria Hendges","family":"SPARVOLI","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-0454","authenticated-orcid":false,"given":"Antonio Cardoso","family":"SPARVOLI","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6580-6417","authenticated-orcid":false,"given":"Carla Vitola","family":"GON\u00c7ALVES","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-boron non-A, non-B viral hepatitis genome","volume":"244","author":"Choo QL","year":"1989","journal-title":"Science"},{"key":"ref2","series-title":"Characterization of the hepatitis C virus core region mutations associated with hepatocellular carcinoma","author":"Moreira JP","year":"2015"},{"key":"ref3","series-title":"Hepatitis C","year":"2018"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study","volume":"388","author":"Stanaway JD","year":"2016","journal-title":"The Lancet"},{"key":"ref5","series-title":"Epidemiological Bulletin \u201cViral Hepatitis\u201d","volume":"Year VI","year":"2018"},{"key":"ref6","series-title":"Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections","year":"2019"},{"key":"ref7","series-title":"Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections","year":"2015"},{"key":"ref8","series-title":"Clinical Practice Guidelines: EASL Recommendations on Treatment of Hepatitis C","year":"2015"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"12","author":"Kohli A","year":"2014","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Guidance Panel (American Association for the Study of Liver Diseases and the Infectious Diseases Society of America). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"ref11","series-title":"Clinical Protocol and Therapeutic Guidelines for Viral Hepatitis C and Coinfections","year":"2013"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of chronic HCV infection with the new direct acting antivirals (DAA): First report of a real world experience in Southern Brazil","volume":"16","author":"Cheinquer H","year":"2017","journal-title":"Ann Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bjid.2018.04.003","article-title":"Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil","volume":"22","author":"Ferreira VL","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11096-017-0552-1","article-title":"Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience","volume":"39","author":"Medeiros T","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group","volume":"24","author":"Bedossa P","year":"1996","journal-title":"Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease","volume":"39","author":"Colloredo G","year":"2003","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey DC","year":"2009","journal-title":"Hepatol"},{"key":"ref18","series-title":"Phase 3, randomized, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na\u00efve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST- 1","author":"Kwo P","year":"2015"},{"key":"ref19","series-title":"Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na\u00efve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST- 2","author":"Lawitz E","year":"2015"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski MS","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"ref21","series-title":"Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study","author":"Poordad F","year":"2015"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz E","year":"2013","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options","volume":"368","author":"Jacobson I","year":"2013","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study","volume":"61","author":"Nelson DR","year":"2015","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40261-018-0624-6","article-title":"Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies","volume":"38","author":"Ferreira VL","year":"2018","journal-title":"Clin Drug Investig"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochoud PY","year":"2009","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou G","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1590\/S0100-879X2005000100007","article-title":"Geographic distribution of hepatitis C virus genotypes in Brazil","volume":"38","author":"Campiotto S","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref30","series-title":"Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections","year":"2018"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v56n4\/1678-4219-ag-56-04-394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T21:16:46Z","timestamp":1596230206000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032019000400394&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["S0004-28032019000400394"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201900000-79","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}